TY - JOUR
T1 - Depot‐medroxyprogesterone acetate (DMPA) and risk of liver cancer
AU - THE WHO COLLABORATIVE STUDY OF NEOPLASIA AND STEROID CONTRACEPTIVES
AU - Mati, J. G.
AU - Kenya, P.
AU - Kungu, A.
AU - Gatei, D.
AU - Silpisoronkosol, Suporn
AU - Pardthaisong, Tieng
AU - Sahapong, Virote
AU - Theetranont, Choti
AU - Boosiri, Banpot
AU - Chutivongse, Supawat
AU - Virutmasen, Pramuan
AU - Wongsrchanalai, Chansuda
AU - Sindhvananda, Sermsri
AU - Koetsawang, Suporn
AU - Rachawat, Daungdao
AU - Koetsawang, Amom
AU - Anthony, P. P.
AU - Thomas, David B.
AU - Noonan, Elizabeth A.
AU - Ray, Roberta M.
AU - Rosenblatt, Karin A.
AU - Stanford, Janet L.
AU - Holck, Susan
AU - Farley, Timothy M.M.
AU - Rosenblatt, Karin A.
AU - Thomas, David B.
PY - 1991/9/9
Y1 - 1991/9/9
N2 - A hospital‐based case‐control study was conducted to assess the possible relationship between use of depot‐medroxy‐progesterone acetate (DMPA), an injectable progestational contraceptive, and the development of liver cancer in 2 developing countries where hepatitis B is endemic. Information about prior DMPA use and potential confounders was ascertained during personal interviews with 71 cases and 530 controls from 3 hospitals in Thailand and 1 hospital in Kenya. No significant association between liver cancer and DMPA use was observed in Kenya (RR = 1.64, 95% CI = 0.4‐0.6) or Thailand (RR = 0.33, 95% CI = 0.1‐1.O). No consistent changes in risk were observed with duration of use, time since last use, or time since first use. No significant associations were observed between DMPA use and risks of either hepatocellular carcinoma or cholangiocarcinoma. These findings suggest that risk of liver cancer in areas where hepatitis B is endemic is not appreciably altered by the use of DMPA.
AB - A hospital‐based case‐control study was conducted to assess the possible relationship between use of depot‐medroxy‐progesterone acetate (DMPA), an injectable progestational contraceptive, and the development of liver cancer in 2 developing countries where hepatitis B is endemic. Information about prior DMPA use and potential confounders was ascertained during personal interviews with 71 cases and 530 controls from 3 hospitals in Thailand and 1 hospital in Kenya. No significant association between liver cancer and DMPA use was observed in Kenya (RR = 1.64, 95% CI = 0.4‐0.6) or Thailand (RR = 0.33, 95% CI = 0.1‐1.O). No consistent changes in risk were observed with duration of use, time since last use, or time since first use. No significant associations were observed between DMPA use and risks of either hepatocellular carcinoma or cholangiocarcinoma. These findings suggest that risk of liver cancer in areas where hepatitis B is endemic is not appreciably altered by the use of DMPA.
UR - http://www.scopus.com/inward/record.url?scp=0025815286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025815286&partnerID=8YFLogxK
U2 - 10.1002/ijc.2910490206
DO - 10.1002/ijc.2910490206
M3 - Article
C2 - 1831801
AN - SCOPUS:0025815286
SN - 0020-7136
VL - 49
SP - 182
EP - 185
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 2
ER -